Other antibodies are currently being investigated for treating MF/SS patients, such as pembrolizumab (an immune checkpoint inhibitor that blocks PD-1) and lacutamab (IPH4102; an anti-KIR3DL2 monoclonal antibody). This evidence concerns the gene PDCD1 and mycosis fungoides.